IN2009DN05758A - - Google Patents

Download PDF

Info

Publication number
IN2009DN05758A
IN2009DN05758A IN5758DEN2009A IN2009DN05758A IN 2009DN05758 A IN2009DN05758 A IN 2009DN05758A IN 5758DEN2009 A IN5758DEN2009 A IN 5758DEN2009A IN 2009DN05758 A IN2009DN05758 A IN 2009DN05758A
Authority
IN
India
Prior art keywords
antibodies
solubility
methods
stability
scfv
Prior art date
Application number
Other languages
English (en)
Inventor
Urech David
Borras Leonardo
Original Assignee
Esbatech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech Ag filed Critical Esbatech Ag
Publication of IN2009DN05758A publication Critical patent/IN2009DN05758A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IN5758DEN2009 2007-03-12 2008-03-12 IN2009DN05758A (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90636507P 2007-03-12 2007-03-12
PCT/EP2008/001958 WO2008110348A1 (en) 2007-03-12 2008-03-12 Sequence based engineering and optimization of single chain antibodies

Publications (1)

Publication Number Publication Date
IN2009DN05758A true IN2009DN05758A (https=) 2015-07-24

Family

ID=39586970

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5758DEN2009 IN2009DN05758A (https=) 2007-03-12 2008-03-12

Country Status (11)

Country Link
US (2) US8280711B2 (https=)
EP (2) EP3202786A3 (https=)
JP (1) JP5622397B2 (https=)
CN (2) CN103275216B (https=)
AU (1) AU2008226067B2 (https=)
CA (1) CA2680564C (https=)
IL (1) IL200710A (https=)
IN (1) IN2009DN05758A (https=)
NZ (1) NZ579594A (https=)
RU (2) RU2009137582A (https=)
WO (1) WO2008110348A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2009DN05758A (https=) 2007-03-12 2015-07-24 Esbatech Ag
US20090074780A1 (en) 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
KR101530723B1 (ko) * 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
PL3241843T3 (pl) 2008-06-25 2021-12-27 Novartis Ag Optymalizacja rozpuszczalności cząsteczek immunowiążących
MX345039B (es) 2008-06-25 2017-01-16 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles que inhiben el tnfa.
LT3216803T (lt) 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
CN104004094B (zh) 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
EP2408814B1 (en) 2009-03-20 2018-11-21 Amgen Inc. Carrier immunoglobulins and uses thereof
US8399624B1 (en) 2009-06-25 2013-03-19 Esbatech, An Alcon Biomedical Research Unit Llc Acceptor framework for CDR grafting
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
WO2012040518A2 (en) 2010-09-22 2012-03-29 Amgen Inc. Carrier immunoglobulins and uses thereof
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
GB201310859D0 (en) * 2013-06-18 2013-07-31 Cambridge Entpr Ltd Rational method for solubilising proteins
EP3761033A3 (en) * 2013-09-06 2021-01-20 F. Hoffmann-La Roche AG Method for improving antibody stability
WO2016044224A1 (en) 2014-09-15 2016-03-24 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
JP6932700B2 (ja) 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド ４価の二重特異性抗原結合タンパク質及び４価の四重特異性抗原結合タンパク質、ならびにそれらの使用
US10822408B2 (en) 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
EP3538555A1 (en) 2016-11-14 2019-09-18 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
UY38050A (es) 2018-01-12 2019-07-31 Amgen Inc Anticuerpos pac1 y sus usos referencia cruzada a solicitudes relacionadas
WO2019233984A1 (en) * 2018-06-08 2019-12-12 Ventana Medical Systems, Inc. Universal or normalized antibody frameworks for improved functionality and manufacturability
JP7500619B2 (ja) 2019-05-30 2024-06-17 アムジエン・インコーポレーテツド 抗体の二量体化を促進するためのヒンジ領域の操作
AU2020304671A1 (en) 2019-06-28 2022-01-20 Amgen Inc. Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins
EP4628498A3 (en) 2019-11-08 2026-03-04 Amgen Inc. Engineering charge pair mutations for pairing of hetero-igg molecules
EP4061838A1 (en) 2019-11-19 2022-09-28 Amgen Inc. Novel multispecific antibody format
MX2022007688A (es) 2019-12-20 2022-07-19 Amgen Inc Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
MX2023002125A (es) 2020-08-20 2023-04-26 Amgen Inc Proteínas de unión a antígenos con disulfuro no canónico en la región fab.
AU2021358033A1 (en) 2020-10-07 2023-05-04 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
WO2022103773A1 (en) 2020-11-10 2022-05-19 Amgen Inc. Novel linkers of multispecific antigen binding domains
CN116848136A (zh) 2021-02-12 2023-10-03 勃林格殷格翰国际有限公司 补体c3抗原结合蛋白
US11912771B2 (en) 2021-03-09 2024-02-27 Cdr-Life Ag MAGE-A4 peptide-MHC antigen binding proteins
EP4304725A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Rabbit-derived antigen binding protein nucleic acid libraries
JP2024515301A (ja) 2021-04-20 2024-04-08 アムジエン・インコーポレーテツド 多重特異性及び一価のｉｇｇ分子の会合における鎖対形成の静電ステアリングにおけるバランスのとれた電荷分布
KR20240116828A (ko) 2021-12-14 2024-07-30 씨디알-라이프 아게 이중 mhc-표적화 t 세포 관여자
IL313655A (en) 2021-12-22 2024-08-01 Boehringer Ingelheim Int Anti-C3 antibodies and their antigen-binding fragments and their uses for the treatment of eyes or eye diseases
KR20250067130A (ko) 2022-09-14 2025-05-14 씨디알-라이프 아게 Mage-a4 펩티드 이중 t 세포 연결체
WO2025210181A1 (en) 2024-04-04 2025-10-09 Cdr-Life Ag Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide
WO2025215160A1 (en) 2024-04-11 2025-10-16 Cdr-Life Ag Antigen binding proteins targeting an hla-restricted prame peptide

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US6740734B1 (en) 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
CN1062312C (zh) * 1996-11-29 2001-02-21 中国科学院微生物研究所 抗ⅳ型胶原酶单链抗体
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
CA2340091C (en) 1998-08-11 2013-02-05 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2040400A (en) 1998-12-14 2000-07-03 Osteotech, Inc. Bone graft and guided bone regeneration method
CN1232039A (zh) * 1999-04-02 1999-10-20 中国人民解放军海军总医院 一种基因工程双特异抗体及其应用
US6602977B1 (en) 1999-04-19 2003-08-05 Biovitrum Ab Receptor structures
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
EP2392596A3 (en) 1999-12-28 2013-11-27 ESBATech, an Alcon Biomedical Research Unit LLC Intrabodies with defined framework that is stable in a reducing environment and applications thereof
CA2901451C (en) 2000-05-10 2020-04-07 Moses Rodriguez Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DK1390535T3 (da) 2001-04-26 2010-12-06 Amgen Mountain View Inc Kombinatoriske biblioteker af monomer-domæner
CA2453662A1 (en) * 2001-07-19 2003-01-30 Stefan Ewert Modification of human variable domains
SI2332989T1 (sl) 2002-05-22 2015-06-30 Esbatech, An Alcon Biomedical Research Unit Llc Imunoglobulinski bralni okvirji, ki kaĺ˝ejo izboljĺ ano stabilnost v intraceliäśnem okolju, in postopki za njihovo identifikacijo
EP1644416A4 (en) * 2003-06-30 2007-08-29 Centocor Inc ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
KR20060120161A (ko) 2003-11-28 2006-11-24 아스트라제네카 아베 항체
EP3225633B1 (en) 2004-05-21 2020-03-25 The UAB Research Foundation Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
GB0416651D0 (en) 2004-07-26 2004-08-25 Proteo Target Aps Polypeptide
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
NZ563580A (en) 2005-06-07 2010-09-30 Esbatech An Alcon Biomedical R Stable and soluble antibodies inhibiting TNFaplha
CN101326195B9 (zh) 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
JP2009542232A (ja) 2006-07-10 2009-12-03 エスバテック・アーゲー 上皮および／または内皮層を通過するｓｃＦｖ抗体
IN2009DN05758A (https=) 2007-03-12 2015-07-24 Esbatech Ag
US20090074780A1 (en) 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
KR101530723B1 (ko) * 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화

Also Published As

Publication number Publication date
EP3202786A3 (en) 2017-10-11
JP2010523077A (ja) 2010-07-15
JP5622397B2 (ja) 2014-11-12
US8280711B2 (en) 2012-10-02
CA2680564A1 (en) 2008-09-18
CN103275216A (zh) 2013-09-04
CN103275216B (zh) 2015-05-06
HK1138602A1 (en) 2010-08-27
US9938336B2 (en) 2018-04-10
US20130053259A1 (en) 2013-02-28
WO2008110348A1 (en) 2008-09-18
RU2014127308A (ru) 2016-02-10
RU2009137582A (ru) 2011-04-20
CA2680564C (en) 2018-05-01
AU2008226067B2 (en) 2012-11-08
IL200710A0 (en) 2010-05-17
EP3202786A2 (en) 2017-08-09
AU2008226067A1 (en) 2008-09-18
IL200710A (en) 2014-07-31
CN101668771B (zh) 2013-08-21
US20100137150A1 (en) 2010-06-03
EP2118138A1 (en) 2009-11-18
NZ579594A (en) 2012-03-30
CN101668771A (zh) 2010-03-10

Similar Documents

Publication Publication Date Title
IN2009DN05758A (https=)
MX2009013327A (es) Ingenieria basada en secuencias y optimizacion de anticuerpos de cadena simple.
MX2009013328A (es) Metodos para modificar anticuerpos, y anticuerpos modificados con propiedades funcionales mejoradas.
MY206610A (en) Antibodies binding to gprc5d
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle
AR083747A1 (es) Anticuerpos anti-il-23
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización
IN2014MN00873A (https=)
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
JO3625B1 (ar) بروتينات رابطة للأنتيجين cd27l
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
PH12015501505A1 (en) Antibodies that bind to tl1a and their uses
DE602006013029D1 (de) Anti-egfr-antikörper
NZ706232A (en) Anti-cd3 antibodies and uses thereof
DOP2011000232A (es) Proteinas de union a il-1
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
ATE431423T1 (de) Verfahren zum screening der leichten kette eines antikörpers
NO20092285L (no) Humane, monoklonale antistoffer til BTLA og fremgangsmater for anvendelse
UA94576C2 (ru) Выделенное антитело, которое связывается с igf-1r, композиция, которая его содержит, и способы, которые касаются антител
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
MXPA06010715A (es) Anticuerpo del receptor del factor de crecimiento humano anti-epidermico.
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9